5/20/2002 - Agilent Technologies Inc. (NYSE: A) and Callida Genomics Inc., a majority-owned subsidiary of Hyseq Pharmaceuticals Inc. (Nasdaq: HYSQ), today announced a non-exclusive licensing agreement that grants Callida both up-front fees and potential running royalties, and gives Agilent access to Callida's early microarray patent portfolio for commercial use in the field of non-universal DNA microarrays. "This license enhances our extensive microarray patent portfolio and furthers our ability to bring new DNA microarray solutions to the life sciences community," said Barney Saunders, vice president and general manager of Agilent's Bioresearch Solutions business. "This agreement secures access to an important set of patents derived from Dr. Radoje Drmanac, currently CSO at Callida, who conducted pioneering work in the early development of microarrays."
Previous Page | News by Category | News Search
If you found this page useful, bookmark and share it on: